Antibodies
21 January 2017
OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Brontictuzumab for the Treatment of Metastatic Colorectal Cancer Patients21 January 2017
Pamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers Symposium18 January 2017
Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review12 January 2017
TG Therapeutics Announces Completion of Enrollment and B-cell Depletion Data from Part 1 of Ongoing Phase 2 Multiple Sclerosis Study12 January 2017
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Trastuzumab12 January 2017
Affimed Provides Update on NK-Cell Immuno-Oncology Platform10 January 2017
ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (anti-PlGF) for Diabetic Macular Edema (DME)9 January 2017
MabVax Therapeutics Files Investigational New Drug Application for Novel Radioimmunotherapy Agent MVT-10759 January 2017
Kymab Expands Infectious Disease Programmes6 January 2017
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization5 January 2017
Seattle Genetics Initiates Phase 1 Trial of SGN-CD352A for Patients with Relapsed or Refractory Multiple MyelomaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports